247 related articles for article (PubMed ID: 15818707)
1. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease.
Lovell DJ; Bowyer SL; Solinger AM
Arthritis Rheum; 2005 Apr; 52(4):1283-6. PubMed ID: 15818707
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome.
Neven B; Marvillet I; Terrada C; Ferster A; Boddaert N; Couloignier V; Pinto G; Pagnier A; Bodemer C; Bodaghi B; Tardieu M; Prieur AM; Quartier P
Arthritis Rheum; 2010 Jan; 62(1):258-67. PubMed ID: 20039428
[TBL] [Abstract][Full Text] [Related]
3. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis.
Verbsky JW; White AJ
J Rheumatol; 2004 Oct; 31(10):2071-5. PubMed ID: 15468378
[TBL] [Abstract][Full Text] [Related]
4. Rapid responses to anakinra in patients with refractory adult-onset Still's disease.
Fitzgerald AA; Leclercq SA; Yan A; Homik JE; Dinarello CA
Arthritis Rheum; 2005 Jun; 52(6):1794-803. PubMed ID: 15934079
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
Lequerré T; Quartier P; Rosellini D; Alaoui F; De Bandt M; Mejjad O; Kone-Paut I; Michel M; Dernis E; Khellaf M; Limal N; Job-Deslandre C; Fautrel B; Le Loët X; Sibilia J; ;
Ann Rheum Dis; 2008 Mar; 67(3):302-8. PubMed ID: 17947302
[TBL] [Abstract][Full Text] [Related]
6. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.
Zeft A; Hollister R; LaFleur B; Sampath P; Soep J; McNally B; Kunkel G; Schlesinger M; Bohnsack J
J Clin Rheumatol; 2009 Jun; 15(4):161-4. PubMed ID: 19363453
[TBL] [Abstract][Full Text] [Related]
7. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis.
Furst DE
Clin Ther; 2004 Dec; 26(12):1960-75. PubMed ID: 15823761
[TBL] [Abstract][Full Text] [Related]
8. Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism.
Rynne M; Maclean C; Bybee A; McDermott MF; Emery P
Ann Rheum Dis; 2006 Apr; 65(4):533-4. PubMed ID: 16531551
[TBL] [Abstract][Full Text] [Related]
9. Bringing the clinical experience with anakinra to the patient.
Cohen SB; Rubbert A
Rheumatology (Oxford); 2003 May; 42 Suppl 2():ii36-40. PubMed ID: 12817094
[TBL] [Abstract][Full Text] [Related]
10. Anakinra: the first interleukin-1 inhibitor in the treatment of rheumatoid arthritis.
Kary S; Burmester GR
Int J Clin Pract; 2003 Apr; 57(3):231-4. PubMed ID: 12723729
[TBL] [Abstract][Full Text] [Related]
11. [Interleukin-1 receptor antagonist anakinra (Kineret) for treatment of rheumatic arthritis].
Rubbert-Roth A; Perniok A
Z Rheumatol; 2003 Aug; 62(4):367-77. PubMed ID: 12928941
[TBL] [Abstract][Full Text] [Related]
12. [Successful treatment of clinical manifestations of Muckle-Wells syndrome with anakinra].
Dybowski F; Jakobs B; Altmeyer P; Braun J
Dtsch Med Wochenschr; 2006 Aug; 131(34-35):1863-6. PubMed ID: 16915547
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study.
Tan AL; Marzo-Ortega H; O'Connor P; Fraser A; Emery P; McGonagle D
Ann Rheum Dis; 2004 Sep; 63(9):1041-5. PubMed ID: 15066864
[TBL] [Abstract][Full Text] [Related]
14. [Interleukin-1 receptor antagonists in the treatment rheumatoid arthritis].
Zoń-Giebel A; Kotulska A; Giebel S; Cader SA; Kucharz EJ
Przegl Lek; 2002; 59(11):916-8. PubMed ID: 12715722
[TBL] [Abstract][Full Text] [Related]
15. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra.
Hawkins PN; Lachmann HJ; Aganna E; McDermott MF
Arthritis Rheum; 2004 Feb; 50(2):607-12. PubMed ID: 14872505
[TBL] [Abstract][Full Text] [Related]
16. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis.
Ostendorf B; Iking-Konert C; Kurz K; Jung G; Sander O; Schneider M
Ann Rheum Dis; 2005 Apr; 64(4):630-3. PubMed ID: 15345502
[TBL] [Abstract][Full Text] [Related]
17. Refractory adult onset Still's disease successfully treated with anakinra.
Vasques Godinho FM; Parreira Santos MJ; Canas da Silva J
Ann Rheum Dis; 2005 Apr; 64(4):647-8. PubMed ID: 15374853
[No Abstract] [Full Text] [Related]
18. Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al.
Martinez-Taboada VM; Fontalba A; Blanco R; Fernández-Luna JL
Arthritis Rheum; 2005 Jul; 52(7):2226-7. PubMed ID: 15986356
[No Abstract] [Full Text] [Related]
19. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.
Nigrovic PA; Mannion M; Prince FH; Zeft A; Rabinovich CE; van Rossum MA; Cortis E; Pardeo M; Miettunen PM; Janow G; Birmingham J; Eggebeen A; Janssen E; Shulman AI; Son MB; Hong S; Jones K; Ilowite NT; Cron RQ; Higgins GC
Arthritis Rheum; 2011 Feb; 63(2):545-55. PubMed ID: 21280009
[TBL] [Abstract][Full Text] [Related]
20. Anakinra for flares of pyogenic arthritis in PAPA syndrome.
Dierselhuis MP; Frenkel J; Wulffraat NM; Boelens JJ
Rheumatology (Oxford); 2005 Mar; 44(3):406-8. PubMed ID: 15637033
[No Abstract] [Full Text] [Related]
[Next] [New Search]
